• Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Little is known about the efficacy and safety of combination targeted therapy for inflammatory bowel diseases (IBD), despite their use in treatment of other immune-mediated disorders. In a review article in the September issue of Clinical Gastroenterology and Hepatology, Robert P. Hirten et al discuss findings from studies of biologic

Read more
  • Are Patients With PSC and Colitis More likely to Have Subclinical Inflammation?

Are Patients With PSC and Colitis More likely to Have Subclinical Inflammation?

Patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) in remission are significantly more likely to have inflammation of the right colon, based on endoscopic and histologic markers, than patients with UC without PSC, researchers report in the January issue of Clinical Gastroenterology and Hepatology. These findings provide insight into cause

Read more
  • Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Rates of adequate serologic response to Haemophilus influenzae B (HiB) and tetanus vaccines are similar among infants born to women with inflammatory bowel diseases (IBD) treated with immunomodulator or biologic agents compared to women who did not receive these immunosuppressive drugs during pregnancy, researchers report in the January issue of Clinical Gastroenterology

Read more
  • Does Consumption of Certain Fatty Acids Increase Risk of Ulcerative Colitis Flares?

Does Consumption of Certain Fatty Acids Increase Risk of Ulcerative Colitis Flares?

Diets with high levels of fatty acids such as myristic acid (found in palm oil, coconut oil, and dairy fats) increased risk of flare in patients with ulcerative colitis (UC), researchers report in the September issue of Clinical Gastroenterology and Hepatology. Their findings, from a prospective study of more than 400 patients

Read more
  • Does Asthma Increase Risk for Inflammatory Bowel Diseases?

Does Asthma Increase Risk for Inflammatory Bowel Diseases?

A population-based case–control study published in the September issue of Clinical Gastroenterology and Hepatology associates asthma with later development of Crohn’s disease (CD) and with ulcerative colitis (UC). Although the etiology of asthma and inflammatory bowel diseases (IBD) are not well understood, they both involve complex interactions among genetic and environmental factors and the

Read more
  • Is Dietary Fiber OK for Patients With Crohn’s Disease or Ulcerative Colitis?

Is Dietary Fiber OK for Patients With Crohn’s Disease or Ulcerative Colitis?

Intake of dietary fiber reduces risk of disease flares in patients with Crohn’s disease, but not ulcerative colitis, researchers report in the August issue of Clinical Gastroenterology and Hepatology. Recommendations to limit dietary fiber should therefore be re-evaluated. Inflammatory bowel diseases (IBD) have been associated with an abnormal mucosal immune response to

Read more
  • Can Microbial Dysbiosis Cause Colonic Inflammation?

Can Microbial Dysbiosis Cause Colonic Inflammation?

Dysbiosis contributes to the pathogenesis of inflammatory bowel diseases (IBD) by altering colonic expression of genes that regulate inflammation and the immune response, researchers report in the July issue of Cellular and Molecular Gastroenterology and Hepatology. An altered intestinal microbiota composition has been associated with IBD. However, it is not

Read more
  • Can Curcumin Treat Mild-to-Moderate Ulcerative Colitis?

Can Curcumin Treat Mild-to-Moderate Ulcerative Colitis?

Addition of curcumin to mesalamine therapy increases its ability to induce clinical and endoscopic remission in patients with mild-to-moderate active ulcerative colitis (UC), researchers show in the August issue of Clinical Gastroenterology and Hepatology. Patients with mild-to-moderate UC are usually treated with oral and/or topical mesalamine. Those who do not

Read more
  • Is FMT Ready for IBD?

Is FMT Ready for IBD?

Despite promising findings from 2 studies of fecal microbiota transplantation (FMT) in patients with ulcerative colitis, the technology should remain in clinical trials and is not ready for routine practice in patients with inflammatory bowel diseases (IBD), write Ari M. Grinspan and Colleen R. Kelly in an editorial. The success of FMT

Read more
  • VEGF Signaling Prevents Senescence in Colorectal Tumors

VEGF Signaling Prevents Senescence in Colorectal Tumors

Vascular endothelial growth factor receptor-2 (VEGFR2) signaling prevents senescence of colorectal cancer cells by inactivating p21, researchers report in the July issue of Gastroenterology. Inactivation of this pathway correlates with survival of patients treated with anti-VEGF cancer drug bevacizumab. VEGF, a growth factor that has been well studied for its

Read more